If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
== In popular culture == The company's direct analysis in real time (DART) mass spectrometry system has appeared on the television program CSI: NY. The JEOL transmission electron microscope JEM 1011 was a base platform for Prometheus (2012 film) science lab microscope.
==== Weak partial androgenic activity ==== CPA, like spironolactone and other steroidal antiandrogens such as chlormadinone acetate and megestrol acetate, is actually not a pure antagonist of the AR – that is, a silent antagonist – but rather appears to be a very weak partial agonist. Clinically, CPA generally functions purely as an antiandrogen, as it displaces much more efficacious endogenous androgens such as testosterone and DHT from interacting with the receptor and thus its net effect is virtually always to lower physiological androgenic activity. But unlike silent antagonists of the AR like nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide, CPA, by virtue of its slight intrinsic activity at the AR, may be unable to fully inhibit androgenic signaling in the body, which may persist to an extent in some tissues such as the prostate gland. In accordance with its albeit weak capacity for activation of the AR, CPA has been found to stimulate androgen-sensitive carcinoma growth in the absence of other androgens, an effect which could be blocked by co-treatment with flutamide. In one study in rodents, DHT-stimulated prostate weight remained 40% above controls with administration of CPA even at the highest dosage, while flutamide was able to completely block the stimulatory effects of DHT. In addition, CPA alone increased prostate weight by 60%, whereas flutamide had no effect.
== History == Setmelanotide was invented at Ipsen. It was initially known as BIM-22493 and then as RM-493 and IRC-022493. It was evaluated in two one-year clinical studies. The first study enrolled 10 participants with obesity and confirmed or suspected POMC or PCSK1 deficiency while the second study enrolled 11 participants with obesity and confirmed or suspected LEPR deficiency; all participants were six years or older. Most participants had lost more than 10% of their initial body weight after a year of treatment. Some participants also reported feeling less hungry. The U.S. Food and Drug Administration (FDA) granted the application for setmelanotide orphan disease designation, breakthrough therapy designation, and priority review. The FDA granted the approval of Imcivree to Rhythm Pharmaceutical, Inc.
New methods for tracking biomolecules have been developed including the use of colorimetric biosensors, photochromic compounds, biomaterials, and electrochemical sensors. Fluorescent labeling is also a common method in which applications have expanded to enzymatic labeling, chemical labeling, protein labeling, and genetic labeling.
==== Mars landings ==== In 1971, the Soviet's Mars 2 successfully established Mars orbit and attempted a soft landing but crashed, becoming the first man-made object to impact Mars. This was shortly followed by Mars 3, a 358 kg lander, which successfully landed but the lander only transmitted data for 14.5 seconds before losing contact. In 1976, NASA followed suit, and put two successful landers on Mars. These were Viking 1 and Viking 2. These landers were significantly larger than the Soviet Mars landers (Viking 1 was 3,527 kilograms). They were able to take the first photographs from the surface of Mars. Viking 1 operated on the surface of Mars for around six years (On November 11, 1982, the Lander stopped operating after getting a faulty command) and Viking 2 for over three years (mission ended in early 1980). Both landers were equipped with a robotic sampler arm which successfully scooped up soil samples and tested them with instruments such as a Gas chromatography–mass spectrometer. The landers measured temperatures ranging from negative 86 degrees Celsius before dawn to negative 33 degrees Celsius in the afternoon. Both landers had issues obtaining accurate results from their seismometers. Photographs from the landers and orbiters surpassed expectations in quality and quantity. The total exceeded 4,500 from the landers and 52,000 from the orbiters.
Sources: en.wikipedia.org
Since independence, Pakistan has aimed to maintain an independent foreign policy. Pakistan's foreign policy and geostrategy focus on the economy, security, national identity, and territorial integrity, as well as building close ties with other Muslim nations. According to foreign policy expert Hasan Askari Rizvi, "Pakistan highlights sovereign equality of states, bilateralism, mutuality of interests, and non-interference in each other's domestic affairs as the cardinal features of its foreign policy."
=== Pharmacokinetics === Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine. The half-life of abrocitinib is 5 hours and the absorption is not affected by food. A higher dose (400–800 mg) would delay the absorption to 1.5–4 hours. A steady plasma concentration of abrocitinib can be obtained within 48 hours of treatments. The dose is one daily, and abrocitinib is metabolized mainly by cytochrome P450 (CYP450) in liver such as CYP2C9, CYP2C19, CYP3A4 and CYP2B6. The major metabolites of abrocitinib are pyrrolidinone pyrimidine (inactive), 2-hydroxypropyl (active), and 3-hydroxypropyl (active). Dose reduction to half is advisable when abrocitinib is taken with strong inhibitors of CYP2C19. According to phase 1 clinical trials on abrocitinib oral dose of 200 mg, hepatic functions were not altered. However, it is advisable to reduce the dose by half in case of reduced renal function. In serious hepatic impairment and final stages of renal disease, Abrocitinib is contraindicated. Some changes may occur during the abrocitinib treatment such as the reduction in platelet counts after 4 weeks of starting Abrocitinib. However, they will return to normal at the end of the treatment. An increase in LDL, HDL, and total cholesterol levels was also recorded after 4 weeks of Abrocitinib treatment. The increased levels depend on the abrocitinib dose (15% increase in LDL with 200 mg dose versus 10% increase with 100 mg).
=== Experimental system === Edward George Bowen joined the team after responding to a newspaper advertisement looking for a radio expert. Bowen had previously worked on ionosphere studies under Appleton, and was well acquainted with the basic concepts. He had also used the RRS' RDF systems at Appleton's request and was known to the RRS staff. After a breezy interview, Watson-Watt and Jock Herd stated the job was his if he could sing the Welsh national anthem. He agreed, but only if they would sing the Scottish one in return. They declined, and gave him the job. Starting with the BBC transmitter electronics, but using a new transmitter valve from the Navy, Bowen produced a system that transmitted a 25 kW signal at 6 MHz (50 metre wavelength), sending out 25 μs long pulses 25 times a second. Meanwhile, Wilkins and L.H. Bainbridge-Bell built a receiver based on electronics from Ferranti and one of the RRS CRTs. They decided not to assemble the system at the RRS for secrecy reasons. The team, now consisting of three scientific officers and six assistants, began moving the equipment to Orfordness on 13 May 1935. The receiver and transmitter were set up in old huts left over from World War I artillery experiments, the transmitter antenna was a single dipole strung horizontally between two 75 foot (23 m) poles, and the receiver a similar arrangement of two crossed wires. The system showed little success against aircraft, although echoes from the ionosphere as far as 1,000 miles away were noted.
After 1945, many of the films of the immediate post-war period can be characterised as Trümmerfilm (rubble film). East German film was dominated by the state-owned film studio DEFA, while the dominant genre in West Germany was the Heimatfilm ("homeland film"). The Academy Award for Best Foreign Language Film ("Oscar") went to the German production The Tin Drum (Die Blechtrommel) in 1979, to Nowhere in Africa (Nirgendwo in Afrika) in 2002, and to The Lives of Others (Das Leben der Anderen) in 2007. Various Germans won an Oscar for their performances in films. The annual European Film Awards ceremony is held every other year in Berlin, home of the European Film Academy. The Berlin International Film Festival known as "Berlinale", awarding the "Golden Bear" and held annually since 1951, is one of the world's leading film festivals. The "Lolas" are annually awarded in Berlin, at the German Film Awards.
These three vascular supplies to the internal nose converge in the Kiesselbach plexus (the Little area), which is a region in the anteroinferior-third of the nasal septum, (in front and below). Furthermore, the nasal vein vascularisation of the nose generally follows the arterial pattern of nasal vascularisation. The nasal veins are biologically significant, because they have no vessel-valves, and because of their direct, circulatory communication to the cavernous sinus, which makes possible the potential intracranial spreading of a bacterial infection of the nose. Hence, because of such an abundant nasal blood supply, tobacco smoking does therapeutically compromise post-operative healing.
Sources: en.wikipedia.org
At the time, a city influenced by US military presence, the restaurant was showing signs of success for its novelty, the first drive-in restaurant in Germany, and had already made headlines in German newspapers. At the time, it was the 2283rd overall founded by the chain. There were already plans to introduce restaurants and drive-ins in other key European markets, such as the United Kingdom, according to the chain's president. Dale Mulder opened up a Lansing, Michigan A&W franchise in 1961. In 1963, Mulder added the bacon cheeseburger to his menu after a customer made repeated orders for bacon to be added to his cheeseburger. Thus A&W is credited with inventing the bacon cheeseburger.
=== Inhalation drug products === In pharmaceutical dry powder manufacturing, jet milling and spray drying are the two established particle-engineering technologies; jet milling is a top-down comminution method, whereas spray drying is a bottom-up process that atomizes an API solution or suspension into droplets that are rapidly dried into solid particles. Emerging alternatives such as spray-freeze drying, thin-film freezing and supercritical-assisted spray drying have been explored for micronization but are not widely implemented and have limited scale-up capability. Micronization is essential to nearly all marketed inhalation therapies, including dry powder inhalers (DPIs), metered-dose inhalers (MDIs) and nebulized suspensions. Drug deposition in the lung is governed by the aerodynamic diameter of the inhaled particles: particles larger than approximately 5 μm impact in the oropharynx and upper airways, while particles smaller than approximately 1 μm are largely exhaled. The 1–5 μm range, often termed the "respirable fraction," deposits in the conducting airways and alveolar region by sedimentation and diffusion. To achieve this size range with the narrow distribution required for reproducible lung dose, inhalation actives — including corticosteroids such as fluticasone propionate and budesonide, β2-agonists such as salbutamol (albuterol) and salmeterol, and anticholinergics such as tiotropium bromide — are routinely micronized by spiral jet milling.
Scientists at the Allen Institute reported that they identified specific cell types in the brains of mice that undergo changes with age and a specific area where many of the changes occur. Researchers at Korea University, Yonsei University, the University of California, Berkeley, and Tufts University found that the protein HMGB1 induces cellular senescence throughout the body and blocking it can inhibit senescence, reduce systemic inflammation, and improve muscle regeneration. An experiment at the Max Planck Institute for the Biology of Ageing in which mice were given Rapamycin and Trametinib found that lifespan and healthspan were significantly extended in both male and female mice. A study at the University of Haifa found that synchronization between organs declines with age except for the immune system, with inflammatory responses becoming more coordinated between different organs the older a person gets. The researchers mapped the biological systems and specific genes involved, suggesting that the discovery could improve diagnostics and with time pave the way to interventions into the process. Researchers at the University of California, San Francisco, reported that the protein FTL1 may be a major cause of brain aging, finding that blocking the protein in mice restored youthful brain function. A study led by Lige Leng of Xiamen University suggested that a drop in the brain protein MEN1 in the hypothalamus may be a driver of physiological aging, and that an amino acid supplement may counter some of the effects.
=== Non-substrate-like inhibitors === Non-substrate-like inhibitors do not take after dipeptidic nature of DPP-4 substrates. They are non-covalent inhibitors and usually have an aromatic ring that occupies the S1-pocket, instead of the proline mimetic. In 1999, Merck started a drug development program on DPP-4 inhibitors. When they started internal screening and medicinal chemistry program, two DPP-4 inhibitors were already in clinical trials, isoleucyl thiazolidide (P32/38) and NVP-DPP728 from Novartis. Merck in-licensed L-threo-isoleucyl thiazolidide and its allo stereoisomer. In animal studies, they found that both isomers had similar affinity for DPP-4, similar in vivo efficacy, similar pharmacokinetic and metabolic profiles. Nevertheless, the allo isomer was 10-fold more toxic. The researchers found out that this difference in toxicity was due to the allo isomer's greater inhibition of DPP-8 and DPP-9 but not because of selective DPP-4 inhibition. More research also supported that DPP-4 inhibition would not cause compromised immune function. Once this link between affinity for DPP-8/DPP-9 and toxicity was discovered, Merck decided on identifying an inhibitor with more than a thousandfold affinity for DPP-4 over the other dipeptidases. For this purpose, they used positional scanning libraries.
== Production == Unlike other aptamers, L-RNA aptamers are not directly made using systematic evolution of ligands by exponential enrichment (SELEX), as L-nucleic acids are not amenable to enzymatic methods, such as polymerase chain reaction (PCR), used in SELEX. Therefore, the selection is done with mirrored target molecules.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.